Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Inhibikase Therapeutics
Biotech
BMS oncology head swings to Syndax—Chutes & Ladders
BMS oncology head swings to Syndax. Stylus unsheathes with Bayer vet at helm. T1D Fund picks up former BMS dealmaker.
Darren Incorvaia
,
Zoey Becker
May 16, 2025 8:30am
Former Inhibikase CEO launches new biotech for Parkinson's asset
May 12, 2025 12:44pm
Private equity firms take over bluebird's nest—Chutes & Ladders
Feb 28, 2025 8:30am
NIH leaders join health agency exodus—Chutes & Ladders
Feb 21, 2025 8:30am
Inhibikase hits pause on Parkinson's program over efficacy
Jan 30, 2025 4:30am
Inhibikase clears another clinical hold, preps new phase 2 trial
Mar 8, 2023 10:18am